as 11-15-2024 12:37pm EST
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
Upcoming Earnings Alert:
Get ready for potential market movements as Molecular Templates Inc. MTEM prepares to release earnings report on 19 Nov 2024.
Founded: | 2001 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 9.7M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 15.9M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.79 | EPS Growth: | N/A |
52 Week Low/High: | $0.30 - $5.45 | Next Earning Date: | 11-19-2024 |
Revenue: | $25,470,000 | Revenue Growth: | -49.41% |
Revenue Growth (this year): | -78.05% | Revenue Growth (next year): | -89.81% |
MTEM Breaking Stock News: Dive into MTEM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Journal-News, Hamilton, Ohio
5 months ago
Motley Fool
5 months ago
TechCrunch
5 months ago
The Telegraph
5 months ago
Simply Wall St.
5 months ago
Bloomberg
5 months ago
Simply Wall St.
5 months ago
The information presented on this page, "MTEM Molecular Templates Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.